Brodalumab

布罗利尤单抗

Report date: 2026/05/14 20:00:28

Base Information

Drug NameBrodalumab
Drug Alias NameBrodalumabum布洛鲁单抗布罗芦单抗布罗利尤单抗柏达鲁单抗 +[13] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin-17 receptor A antagonists
TargetsInterleukin-17 receptor A
Therapy Area/IndicationsPlaque psoriasisNon-radiographic axial spondyloarthritisPalmoplantar pustulosis +[31] 
Global Approved IndicationsPlaque psoriasisPsoriasisArthritis, Psoriatic
Approved Indications in ChinaPlaque psoriasis
Original Approved Country/TerritoryJapan
Original Approved Date2016/07/04
Country/TerritoryCzechiaBelgiumBulgaria +[34] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesKyowa Kirin Co LtdKyowa KirinValeant Pharmaceuticals Luxembourg Sarl +[6] 
Inactive CompaniesFlorida Academic Dermatology Centers LlcAstrazeneca PlcLeo Pharma Inc +[7] 
Active IndicationsPlaque psoriasisNon-radiographic axial spondyloarthritisSolid tumours +[25] 
Inactive IndicationsPalmoplantar pustulosisPustular psoriasisAxial Spondyloarthritis +[6] 

Other Information

ATC CodeL04AC12
Related LinksWikipediaKEGG